Combination therapy and methods for treating bacterial biofilms
A combination therapy for treating a bacterial biofilm comprises a therapeutically effective amount of an antibiotic comprising an aminoglycoside or tetracycline, or a combination of two or more thereof, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa comprises contacting the bacterial biofilm with a combination therapy comprising a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa in a patient comprises administering to the patient a combination therapy comprising a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.
1. A formulation for treating a bacterial biofilm, comprising a therapeutically effective amount of an antibiotic comprising an aminoglycoside or tetracycline, or a combination of two or more thereof, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.
2. The formulation of claim 1 , wherein the antibiotic comprises an aminoglycoside.
3. The formulation of claim 1 , wherein the cationic porphyrin comprises 5,10,15,20-tetrakis(1-methyl-pyridino)-21H,23H-porphine, tetra-p-tosylate salt (TMP).
4. The formulation of claim 3 , wherein the antibiotic comprises tobramycin.
5. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa , comprising contacting the bacterial biofilm with a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.
6. The method of claim 5 , wherein the method is conducted without photoactivation of the cationic porphyrin.
7. The method of claim 5 , wherein the cationic porphyrin is photoactivated.
8. The method of claim 5 , wherein the antibiotic comprises an aminoglycoside, glycopeptide or tetracycline, or a combination of two or more thereof.
9. The method of claim 5 , wherein the cationic porphyrin comprises 5,10,15,20-tetrakis(1-methyl-pyridino)-21H,23H-porphine, tetra-p-tosylate salt (TMP).
10. The method of claim 9 , wherein the antibiotic comprises tobramycin and/or vancomycin.
11. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa in a patient, comprising administering to the patient a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.
12. The method of claim 11 , wherein the bacterial biofilm is a lung biofilm of a cystic fibrosis patient.
13. The method of claim 11 , wherein the bacterial biofilm is on one or more teeth of the patient.
14. The method of claim 11 , wherein the method is conducted without photoactivation of the cationic porphyrin.
15. The method of claim 11 , wherein the antibiotic comprises an aminoglycoside, glycopeptide or tetracycline, or a combination of two or more thereof.
16. The method of claim 11 , wherein the antibiotic comprises an aminoglycoside and/or a glycopeptides.
17. The method of claim 11 , wherein the cationic porphyrin comprises 5,10,15,20-tetrakis(1-methyl-pyridino)-21H,23H-porphine, tetra-p-tosylate salt (TMP).
18. The method of claim 17 , wherein the antibiotic comprises tobramycin or vancomycin.
19. The method of claim 17 , wherein the antibiotic comprises tobramycin.
20. The method of claim 11 , wherein the antibiotic and cationic porphyrin are administered sequentially.
21. The method of claim 11 , wherein the antibiotic and cationic porphyrin are administered simultaneously.